MRSN•benzinga•
Mersana Therapeutics Announces Additional Interim Phase 1 Clinical Data For Emiltatug Ledadotin, B7-H4-Directed Dolasynthen ADC
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga